- Home
- RMAX vs CYBN Comparison
RMAX vs CYBN Comparison
Compare RMAX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- CYBN
- Stock Information
- Founded
- RMAX 1973
- CYBN 2019
- Country
- RMAX United States
- CYBN Canada
- Employees
- RMAX N/A
- CYBN N/A
- Industry
- RMAX Real Estate
- CYBN Pharmaceuticals and Biotechnology
- Sector
- RMAX Finance
- CYBN Health Care
- Exchange
- RMAX Nasdaq
- CYBN Nasdaq
- Market Cap
- RMAX 178.3M
- CYBN 176.5M
- IPO Year
- RMAX 2013
- CYBN N/A
- Fundamental
- Price
- RMAX $9.92
- CYBN $5.99
- Analyst Decision
- RMAX Hold
- CYBN Strong Buy
- Analyst Count
- RMAX 1
- CYBN 3
- Target Price
- RMAX $9.00
- CYBN $85.00
- AVG Volume (30 Days)
- RMAX 212.6K
- CYBN 617.8K
- Earning Date
- RMAX 10-30-2025
- CYBN 11-12-2025
- Dividend Yield
- RMAX N/A
- CYBN N/A
- EPS Growth
- RMAX N/A
- CYBN N/A
- EPS
- RMAX 0.48
- CYBN N/A
- Revenue
- RMAX $298,162,000.00
- CYBN N/A
- Revenue This Year
- RMAX N/A
- CYBN N/A
- Revenue Next Year
- RMAX N/A
- CYBN N/A
- P/E Ratio
- RMAX $20.66
- CYBN N/A
- Revenue Growth
- RMAX N/A
- CYBN N/A
- 52 Week Low
- RMAX $6.90
- CYBN $4.81
- 52 Week High
- RMAX $14.31
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- RMAX 63.07
- CYBN 38.18
- Support Level
- RMAX $9.64
- CYBN $5.90
- Resistance Level
- RMAX $9.92
- CYBN $6.19
- Average True Range (ATR)
- RMAX 0.31
- CYBN 0.45
- MACD
- RMAX 0.02
- CYBN -0.04
- Stochastic Oscillator
- RMAX 70.80
- CYBN 9.09
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.